Quarterly report [Sections 13 or 15(d)]

Nature of Operations and Basis of Presentation - Accounting for Derivative Instruments (Details)

v3.26.3
Nature of Operations and Basis of Presentation - Accounting for Derivative Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Jun. 12, 2026
Dec. 31, 2025
Nature of Operations and Basis of Presentation [Line Items]            
Deferred NPNS assets $ 669   $ 669     $ 0
Current portion of deferred NPNS liabilities (103)   (103)     0
Deferred NPNS liabilities (1,055)   (1,055)     $ 0
Total deferred NPNS assets and liabilities         $ (520)  
Deferred NPNS Assets and Liabilities Amortization [Abstract]            
2026(1) [1]         57  
2027         103  
2028         103  
2029         88  
2030         58  
Thereafter         111  
Total estimated amortization         520  
(Increase) Reduction to Cost of Sales From Amortization Of NPNS Assets And Liabilities 26   31      
Derivative gain (loss), net $ (1) $ 0 0 $ 0    
Balance Sheet Location [Axis]: cqp:DeferredNormalPurchaseNormalSaleAssets            
Nature of Operations and Basis of Presentation [Line Items]            
Deferred NPNS assets         669  
Balance Sheet Location [Axis]: cqp:DeferredNormalPurchaseNormalSaleCurrentLiabilities            
Nature of Operations and Basis of Presentation [Line Items]            
Current portion of deferred NPNS liabilities         (108)  
Balance Sheet Location [Axis]: cqp:DeferredNormalPurchaseNormalSaleLiabilities            
Nature of Operations and Basis of Presentation [Line Items]            
Deferred NPNS liabilities         $ (1,081)  
Normal Purchase Normal Sale Designated            
Deferred NPNS Assets and Liabilities Amortization [Abstract]            
Derivative gain (loss), net   $ 127 $ (126) $ 315    
[1] For the three and nine months ended September 30, 2026, we recorded a net reduction to cost of sales from amortization of $26 million and $31 million, respectively.